<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39402091</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing.</ArticleTitle><Pagination><StartPage>23974</StartPage><MedlinePgn>23974</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23974</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-74502-5</ELocationID><Abstract><AbstractText>The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness. This retrospective study included 716 patients who received nirmatrelvir-ritonavir (NR group) or azvudine (FNC group) at Peking Union Medical College Hospital between 1 November 2022 and 27 February 2023. Patients in the FNC group (n = 304) were younger, exhibited less severe symptoms, started antiviral therapy later, received corticosteroids more frequently, and used tocilizumab less frequently than patients in the NR group (n = 412). Within 28 d of therapy, 40 (9.7%) and 20 (6.6%) deaths were in the NR and FNC groups, respectively. No differences were observed between drugs and mortality rates (odds ratio [OR] 0.78, 95% CI 0.40-1.5, P = 0.45), clinical improvement (OR 0.79, 95% CI 0.79-1.3, P = 0.38), and clinical progression (OR 1.0, 95% CI 0.58-1.8, P = 0.96). More patients in the NR group experienced platelet decline than those in the FNC group (17.6% vs. 8.9%, P = 0.034). This study indicated that the effectiveness and safety of azvudine were comparable to those of nirmatrelvir-ritonavir.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xie</LastName><ForeName>Huaiya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Yaqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Luo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Junping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiaoxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaobei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yanli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinglan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Aohua</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xueqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jihai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Huadong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xinlun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China. tianxl@pumch.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking Union Medical College Hospital, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China. tianxl@pumch.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mengzhao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China. mengzhaowang@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking Union Medical College Hospital, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China. mengzhaowang@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021-I2M-1-048</GrantID><Agency>Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences</Agency><Country /></Grant><Grant><GrantID>2023YFC3041900</GrantID><Agency>National Key Research and Development Program of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Azvudine</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Nirmatrelvir-ritonavir</Keyword><Keyword MajorTopicYN="N">Seven-category ordinal scale</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39402091</ArticleId><ArticleId IdType="pmc">PMC11473676</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-74502-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-74502-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Institutes of Health (USA). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, &lt;https://www.covid19treatmentguidelines.nih.gov/&gt; (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med.386, 1397–1408. 10.1056/NEJMoa2118542 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>National Medical Products Administration. Domestically developed drug joins virus battle, &lt;http://english.nmpa.gov.cn/2022-08/15/c_797867.htm&gt; (2022).</Citation></Reference><Reference><Citation>Ren, Z. et al. A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. Adv. Sci. (Weinh)7, e2001435, 10.1002/advs.202001435 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404576</ArticleId><ArticleId IdType="pubmed">35403380</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science374, 1586–1593. 10.1126/science.abl4784 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesko, B. et al. Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients. Clinical Infectious Diseases75, 2049–2050. 10.1093/cid/ciac588 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35869852</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny, R. et al. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin. Infect. Dis.10.1093/cid/ciac443 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, B. &amp; Chang, J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct. Target Ther.5, 236. 10.1038/s41392-020-00351-z (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547293</ArticleId><ArticleId IdType="pubmed">33040075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, J. L. et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct. Target. Ther.6, 414. 10.1038/s41392-021-00835-6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646019</ArticleId><ArticleId IdType="pubmed">34873151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Y. et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J. Infect.86, e158–e160. 10.1016/j.jinf.2023.03.023 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10062713</ArticleId><ArticleId IdType="pubmed">37003523</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, V. T. et al. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Intern. Med.182, 701–709. 10.1001/jamainternmed.2022.1827 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9055515</ArticleId><ArticleId IdType="pubmed">35486394</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, G. et al. Real-world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID-19: A retrospective cohort study. J. Med. Virol.95, 10.1002/jmv.28756 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37185838</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet370, 1453–1457. 10.1016/s0140-6736(07)61602-x (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez, J. A. et al. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest158, 1896–1911. 10.1016/j.chest.2020.05.598 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297164</ArticleId><ArticleId IdType="pubmed">32561442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Comparative Outcomes of Adults Hospitalized With Seasonal Influenza A or B Virus Infection: Application of the 7-Category Ordinal Scale. Open Forum Infect. Dis.6, ofz053, 10.1093/ofid/ofz053 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6419989</ArticleId><ArticleId IdType="pubmed">30895200</ArticleId></ArticleIdList></Reference><Reference><Citation>General Office of the National Health Commission. Diagnosis and treatment protocol for COVID-19 in China (trial version 10). &lt;https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm&gt; (</Citation></Reference><Reference><Citation>US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet], 2017., &lt;https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf &gt; (</Citation></Reference><Reference><Citation>Zhang, Z., Kim, H. J., Lonjon, G. &amp; Zhu, Y. Balance diagnostics after propensity score matching. Ann. Transl. Med.7, 16. 10.21037/atm.2018.12.10 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351359</ArticleId><ArticleId IdType="pubmed">30788363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>